Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14956464 | 0.85 | HTT (0.54) | HTTSMN1; SMN2LMNACHRNA7CHRNA10 | |
| SCHEMBL14961830 | 0.82 | HTT (0.56) | HTTSMN1; SMN2LMNACHRNA7CHRNA10 | |
| SCHEMBL17640894 | 0.79 | NOTUM (0.48) | HTTSMN1; SMN2LMNACHRNA7CHRNA10 | |
| SCHEMBL24270121 | 0.77 | KDM4E (0.50) | HTTSMN1; SMN2LMNAPIK3CARAB9A | |
| SCHEMBL17640920 | 0.74 | SMN1; SMN2 (0.41) | HTTSMN1; SMN2LMNARAB9AMAPT | |
| SCHEMBL6209994 | 0.71 | MAPT (0.43) | LMNARAB9AMAPTMEN1KMT2A | |
| SCHEMBL221069 | 0.71 | ADORA2A (0.42) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL28640180 | 0.71 | LMNA (0.61) | HTTSMN1; SMN2LMNAPIK3CARAB9A | |
| SCHEMBL24269959 | 0.71 | KDM4E (0.44) | HTTSMN1; SMN2LMNARAB9AMAPT | |
| SCHEMBL2060797 | 0.70 | LGMN (0.64) | HTTSMN1; SMN2LMNACHRNA7CHRNA10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3197895-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | ITGAV, ITGB6, ITGB1 | HTT 4514/4885SMN1; SMN2 2791/4885LMNA 2882/4885 |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | ITGAV, ITGB6, ITGB1 | HTT 4553/4885SMN1; SMN2 3236/4885LMNA 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.